. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Cancer Prev Res (Phila). 2010 May 18;3(6):764–775. doi: 10.1158/1940-6207.CAPR-09-0161

Table 2.

Association between serum interleukin-6 concentrations and flavonol intake during the trial (n = 872)

Interleukin-6 (in pg/mL)	Flavonol Intake Quartiles (in mg/d)^*
	Q1: < 21.1	Q2: 21.1–29.6	Q3: 29.7–40.0	Q4: >40.0

	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	P-value
Sample size	218	218	218	218
Baseline (T0)	2.02 (1.41–2.99)	1.90 (1.38–2.97)	1.79 (1.32–2.75)	1.95 (1.31–2.69)	0.30
Year 1 (T1)	2.05 (1.41–3.23)	2.00 (1.37–3.00)	1.77 (1.26–2.46)	1.83 (1.26–2.72)	0.008
Year 3 (T3)	2.30 (1.62–3.46)	2.07 (1.58–3.25)	1.99 (1.41–2.76)	1.84 (1.35–2.64)	0.0002
Trial (T1,3^‡)	2.20 (1.61–3.19)	2.07 (1.54–2.98)	1.84 (1.37–2.51)	1.80 (1.39–2.60)	0.0002
Change (T1,3–T0^‡)	0.17 (−.30–0.60)	0.19 (−.54–0.67)	−.01 (−.40–0.44)	0.01 (−.51–0.48)	0.07

Participants were grouped in quartiles (Q1–Q4) by mean flavonol intake during the first 3 trial years.

^†

P values for differences in medians among the flavonol intake quartiles were calculated based on the Kruskal-Wallis test. The P value for trend using a multiple regression model adjusting for age tertiles (<58, 58–66, >66 yrs), sex, average BMI (<25, 25.0–29.9, ≥30 kg/m²), current smoking status, and average energy intake (continuous) during the first 3 trial years was 0.01 for Trial (T1,3) and 0.10 for Change (T1,3–T0).

^‡

Trial (T1,3) = geometric mean of the year 1 and 3 values. Change (T1,3–T0) = T1,3 minus baseline values.